Cargando…

Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Immune-checkpoint inhibitors (ICI) have revolutionized the therapeutic landscape of cancer. However, optimal patient selection is still an unmet need. One-hundred-forty-six patients with metastatic cancer candidates to ICI at the Hospital Clinic of Barcelona Clinical Trials Unit were prospectively r...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Corbacho, Javier, Indacochea, Alberto, González Navarro, Azucena E., Victoria, Iván, Moreno, Débora, Pesántez, David, Angelats, Laura, Modrego-Sanchez, Andrea, Sanfeliu, Esther, Castillo, Oleguer, Blasco, Paula, Mezquita, Laura, Viñolas, Nuria, Nogué, Miquel, Galván, Patricia, Adamo, Barbara, Basté, Neus, Sauri, Tamara, Juan, Manel, Prat, Aleix, Schettini, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198872/ https://www.ncbi.nlm.nih.gov/pubmed/36625938 http://dx.doi.org/10.1007/s00262-022-03360-9

Ejemplares similares

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study
por: García-Corbacho, Javier, et al.
Publicado: (2023)

Case Report: A Case Study Documenting the Activity of Atezolizumab in a PD-L1-Negative Triple-Negative Breast Cancer
por: Brasó-Maristany, Fara, et al.
Publicado: (2021)

Dissecting the biological heterogeneity of HER2-positive breast cancer
por: Schettini, Francesco, et al.
Publicado: (2021)

Frequency and spectrum of PIK3CA somatic mutations in breast cancer
por: Martínez-Sáez, Olga, et al.
Publicado: (2020)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Intrinsic molecular subtypes of HER2+ breast cancer
por: Prat, Aleix, et al.
Publicado: (2017)

A perspective on the development and lack of interchangeability of the breast cancer intrinsic subtypes
por: Schettini, Francesco, et al.
Publicado: (2022)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case—Cohort Study
por: El Husseini, Kinan, et al.
Publicado: (2021)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Gene expression profiles of breast cancer metastasis according to organ site
por: Brasó‐Maristany, Fara, et al.
Publicado: (2021)

Revisiting the PD-1 pathway
por: Patsoukis, Nikolaos, et al.
Publicado: (2020)

Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report
por: Schettini, Francesco, et al.
Publicado: (2022)

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
por: Puccini, Alberto, et al.
Publicado: (2020)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy
por: Chic, Nuria, et al.
Publicado: (2021)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic Associations Comprising Anti-PD-1/PD-L1 in Breast Cancer: Clinical Challenges and Perspectives
por: Ledys, Fanny, et al.
Publicado: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
por: Jimbu, Laura, et al.
Publicado: (2021)

Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy
por: Martínez-Sáez, Olga, et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8(+) T Cell Response in Hepatocellular Carcinoma
por: Peña-Asensio, Julia, et al.
Publicado: (2021)

Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer
por: Basté Rotllan, Neus
Publicado: (2022)

Imaging of Dopamine in PD and Implications for Motor and Neuropsychiatric Manifestations of PD
por: de la Fuente-Fernández, Raúl
Publicado: (2013)

The Evolution of Pd(0)/Pd(II)-Catalyzed Aromatic Fluorination
por: Sather, Aaron C., et al.
Publicado: (2016)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Photoluminescence of PdS(2) and PdSe(2) quantum dots
por: Wang, Xinyu, et al.
Publicado: (2019)

PD-1/PD-L Axis in Neuroinflammation: New Insights
por: Manenti, Susanna, et al.
Publicado: (2022)

Interlayer Coordination of Pd–Pd Units in Exfoliated Black Phosphorus
por: Vanni, Matteo, et al.
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

(CAAC)Pd(py) Catalysts Disproportionate to Pd(CAAC)(2)
por: Marigo, Nicola, et al.
Publicado: (2023)

Addressing Peritoneal Dialysis: In Vitro PD Models, In Vivo Rodent PD Model, Clinical Biobanks, and Underutilization of PD
por: Beelen, Robert H. J., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nn5j6najcufq5r1epd7sjhv0l4